CYRX

Cryoport Inc. (CYRX) | Rumor.io

Cryoport

CYRX

Attention (50-day avg)0%

Attention rank (50-day avg)#3,004

Bullish sentiment (50-day avg)100%

Price to earnings ratio12.4

Market capitalization880.3M

Earnings per share-0.82

Dividend yield (TTM)—

Revenue (annual)176.2M

Net income (annual)78.3M

Social

What share of all stock conversation is about CYRX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% +0

May 8

$CYRX dips to a 5/5 gap, setting up a potential gap-and-go trade.
The post expresses a neutral sentiment, referring to the stock as a "dingleberry" that may be able to stay in the teens.
The author is speculating about the stock's potential price movement.

Generated by AI

Sentiment

Of the messages about CYRX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	99.11% +5.71
Bearish	—	—	—	0.89% -5.71

Bullish· Aug 6

$CYRX has been upgraded to Outperform by Leerink, with a price target of $16, citing continued strength in cell and gene therapy market services.
Cryoport's Q2 revenue has increased by 14% to $45.5M, driven by a 33% growth in cell and gene therapy, and the company has a $426M cash war chest.
$CYRX is trading below its cash value, with annual revenues expected to be half the market capitalization, indicating potential for a significant price increase.

Bearish· Jul 13

$CYRX longs get you deserve a piece of crap company that lied to investors.
$CYRX's Q2 and FY23 revenue guidance fell below consensus, leading to a significant price drop.
$CYRX's poor earnings and guidance led to a 25% drop in price, with some analysts predicting further declines to under $15 or an EV of $600mm.

Generated by AI

Topics

Of the messages about CYRX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	78.11%
Analysts	—	—	—	3.13%
Controversies	—	—	—	0%
Earnings	—	—	—	2.26%
Macro	—	—	—	0%
Technical Analysis	—	—	—	16.51%

Earnings· Aug 9

CryoPort, Inc. (CYRX) missed earnings per share (EPS) estimates by $0.03, but beat revenue expectations.
CYRX reported a loss of $0.09 per share, which was worse than the consensus estimate of a loss of $0.07 per share.
The company slightly beat revenue estimates, but the earnings miss was significant.

Announcements· May 6

Cryoport, Inc. ($CYRX) has partnered with LabConnect to provide comprehensive logistics support for an upcoming Phase I/II clinical trial sponsored by Triumvira Immunologics Inc.
The partnership aims to support the innovative Triumvira Cell and Gene Therapy Clinical Trial, leveraging Cryoport's expertise in temperature-controlled logistics.
Cryoport, Inc. ($CYRX) has filed its Form 10-Q quarterly report with the SEC, providing investors with an update on the company's financial performance.

Generated by AI

Community

Of the messages about CYRX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	3.33%	5.53%
Newcomers	—	—	96.67%	94.47%

Regulars· Jul 13

Cryoport's (CYRX) shares fell 29% after the company issued a revenue warning, citing preliminary Q2 numbers that were lower than expected.
B. Riley Securities cut Cryoport's (CYRX) price target to $22.00, following the disappointing revenue update.
Cryoport (CYRX) announced preliminary Q2 results and updated its 2023 revenue expectations, with the company's stock price taking a significant hit.

Newcomers· Aug 6

Analysts at Keybanc and Leerink are optimistic about Cryoport, Inc. (CYRX), with Keybanc overweight and Leerink upgrading the stock to Outperform from Market Perform, citing continued strength in cell and gene therapy market services.
The company's recent Q2 2025 revenue of $45.5M, up 14% year-over-year, has contributed to a significant increase in stock price, with CYRX up 25% premarket and a 27.4% gain in the previous day.
Cryoport, Inc. has secured a major partnership with DHL, selling CRYOPDP to the logistics company for ~$200M, and has also expanded its global reach with a new DHL partnership, positioning the company for future growth.

Generated by AI

The latest analyst work on Cryoport points to a higher blended fair value estimate, with price targets moving from US$17.06 to US$19.33, about a 13% uplift in the modeled target level. That shift lines up with more constructive Street commentary, as several bullish analysts highlight Cryoport’s Cell and Gene Therapy logistics and bioservices as key supports for the higher target range. As you read on, you will see how to track these shifting assumptions and what they might mean for your own...

1mo agoYahoo Finance UK

Cryoport Inc. Earnings Call Signals Cautious Upside

Detailed price information for Cryoport Inc (CYRX-Q) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

Cryoport (CYRX) Q2 2026 Earnings Call Transcript

CGT services revenue surged 15% as clinical trial support expanded to 779 trials globally.

1mo agoYahoo Finance

Cryoport president, CEO Shelton sells $429k in stock via 10b5-1 plan

1mo agoInvesting.com

CryoPort (CYRX) Upgraded to Buy: Here's Why

CryoPort (CYRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

1mo agoYahoo Finance

Also Discussed

Investors talking about CYRX also mention

#	Name	Attention
1	BioLife Solutions Inc.BLFS	0%0
2	Champions Oncology, Inc.CSBR	0%0
3	Delcath Systems, Inc.DCTH	0%new
4	Corcept Therapeutics Inc.CORT	0%new
5	Autolus Therapeutics plc ADRAUTL	0%+0
6	DPSI - Decisionpoint Systems, Inc.	——
7	GSS - Golden Star Resources Ltd.	——
8	PFSW - PFSweb, Inc.	——
9	GSI Technology Inc.GSIT	0%0
10	ORGS - Orgenesis Inc.	——

Cryoport Inc.

Industrials
Integrated Freight & Logistics

Cryoport Inc. is a global life sciences logistics and services company focused on temperature-controlled supply chain solutions for biologic materials. Cryoport Inc. supports the movement, storage, handling, and monitoring of sensitive products used in cell and gene therapy, biopharmaceuticals, animal health, and reproductive medicine. Its current offerings include specialized bio-logistics, bio-storage, bio-processing, cryopreservation, and cryogenic equipment, along with related software and monitoring tools designed to help maintain product integrity throughout transit and storage. Through its Life Sciences Services and Life Sciences Products segments, Cryoport Inc. serves biotechnology and pharmaceutical companies, contract research organizations, fertility clinics, and other healthcare-focused customers worldwide. Headquartered in Brentwood, Tennessee, Cryoport Inc. plays an important role in the infrastructure that supports advanced therapies and other temperature-sensitive life sciences applications.

Website

Location

112 Westwood Place

Brentwood, TN, 37027

United States

Social

What share of all stock conversation is about CYRX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% +0

May 8

$CYRX dips to a 5/5 gap, setting up a potential gap-and-go trade.
The post expresses a neutral sentiment, referring to the stock as a "dingleberry" that may be able to stay in the teens.
The author is speculating about the stock's potential price movement.

Generated by AI

Sentiment

Of the messages about CYRX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	99.11% +5.71
Bearish	—	—	—	0.89% -5.71

Bullish· Aug 6

$CYRX has been upgraded to Outperform by Leerink, with a price target of $16, citing continued strength in cell and gene therapy market services.
Cryoport's Q2 revenue has increased by 14% to $45.5M, driven by a 33% growth in cell and gene therapy, and the company has a $426M cash war chest.
$CYRX is trading below its cash value, with annual revenues expected to be half the market capitalization, indicating potential for a significant price increase.

Bearish· Jul 13

$CYRX longs get you deserve a piece of crap company that lied to investors.
$CYRX's Q2 and FY23 revenue guidance fell below consensus, leading to a significant price drop.
$CYRX's poor earnings and guidance led to a 25% drop in price, with some analysts predicting further declines to under $15 or an EV of $600mm.

Generated by AI

Topics

Of the messages about CYRX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	78.11%
Analysts	—	—	—	3.13%
Controversies	—	—	—	0%
Earnings	—	—	—	2.26%
Macro	—	—	—	0%
Technical Analysis	—	—	—	16.51%

Earnings· Aug 9

CryoPort, Inc. (CYRX) missed earnings per share (EPS) estimates by $0.03, but beat revenue expectations.
CYRX reported a loss of $0.09 per share, which was worse than the consensus estimate of a loss of $0.07 per share.
The company slightly beat revenue estimates, but the earnings miss was significant.

Announcements· May 6

Cryoport, Inc. ($CYRX) has partnered with LabConnect to provide comprehensive logistics support for an upcoming Phase I/II clinical trial sponsored by Triumvira Immunologics Inc.
The partnership aims to support the innovative Triumvira Cell and Gene Therapy Clinical Trial, leveraging Cryoport's expertise in temperature-controlled logistics.
Cryoport, Inc. ($CYRX) has filed its Form 10-Q quarterly report with the SEC, providing investors with an update on the company's financial performance.

Generated by AI

Community

Of the messages about CYRX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	3.33%	5.53%
Newcomers	—	—	96.67%	94.47%

Regulars· Jul 13

Cryoport's (CYRX) shares fell 29% after the company issued a revenue warning, citing preliminary Q2 numbers that were lower than expected.
B. Riley Securities cut Cryoport's (CYRX) price target to $22.00, following the disappointing revenue update.
Cryoport (CYRX) announced preliminary Q2 results and updated its 2023 revenue expectations, with the company's stock price taking a significant hit.

Newcomers· Aug 6

Analysts at Keybanc and Leerink are optimistic about Cryoport, Inc. (CYRX), with Keybanc overweight and Leerink upgrading the stock to Outperform from Market Perform, citing continued strength in cell and gene therapy market services.
The company's recent Q2 2025 revenue of $45.5M, up 14% year-over-year, has contributed to a significant increase in stock price, with CYRX up 25% premarket and a 27.4% gain in the previous day.
Cryoport, Inc. has secured a major partnership with DHL, selling CRYOPDP to the logistics company for ~$200M, and has also expanded its global reach with a new DHL partnership, positioning the company for future growth.

Generated by AI

Cryoport

Social

May 8

Bullish· Aug 6

Bearish· Jul 13

Earnings· Aug 9

Announcements· May 6

Regulars· Jul 13

Newcomers· Aug 6

Cryoport: Strong Pipeline Of Cell And Gene Therapy Approvals (NASDAQ:CYRX)

Cryoport (CYRX) Stock Fair Value Rises After Analysts Lift Growth Assumptions

Cryoport Inc. Earnings Call Signals Cautious Upside

Cryoport (CYRX) Q2 2026 Earnings Call Transcript

Cryoport president, CEO Shelton sells $429k in stock via 10b5-1 plan

CryoPort (CYRX) Upgraded to Buy: Here's Why

Also Discussed

Cryoport Inc.

Company Information

Location

Cryoport: Strong Pipeline Of Cell And Gene Therapy Approvals (NASDAQ:CYRX)

Cryoport (CYRX) Stock Fair Value Rises After Analysts Lift Growth Assumptions

Cryoport Inc. Earnings Call Signals Cautious Upside

Cryoport (CYRX) Q2 2026 Earnings Call Transcript

Cryoport president, CEO Shelton sells $429k in stock via 10b5-1 plan

CryoPort (CYRX) Upgraded to Buy: Here's Why

Also Discussed

Social

May 8

Bullish· Aug 6

Bearish· Jul 13

Earnings· Aug 9

Announcements· May 6

Regulars· Jul 13

Newcomers· Aug 6